FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2118309105> ?p ?o ?g. }

• W2118309105 endingPage "172" @default.
• W2118309105 startingPage "161" @default.
• W2118309105 abstract "It is widely believed that most antidepressant medications exhibit a delay of 2-4 weeks before clinically relevant improvement can be observed among patients. During this latency period, patients continue to be symptomatic and functionally impaired. Thus, time to onset of effect is an important attribute of a new pharmacotherapy. We assessed the onset of effect for duloxetine, utilizing analytical methods previously recommended in the literature.Efficacy data were pooled from two identical, but independent, randomized, double-blind, placebo-controlled, 9-week clinical trials of duloxetine (60 mg QD). Efficacy measures included the 17-item Hamilton Rating Scale for Depression (HAMD(17)), HAMD(17) subscales (Maier, core, and anxiety), and the Clinical Global Impression of Severity (CGI-S) and Patient Global Impression of Improvement (PGI-I) scales. In each individual study, duloxetine demonstrated statistically significant advantages over placebo on multiple outcomes. The present analysis utilized pooled data to more accurately and fully characterize the onset of effect for duloxetine.Median times to sustained improvements of 10% and 20% in the HAMD(17) total score among duloxetine-treated patients were 14 days and 21 days, respectively, compared with 34 days and 49 days, respectively, for placebo-treated patients (p < 0.001 for both results). The median time to sustained 30% improvement in HAMD(17) total score was 35 days for duloxetine-treated patients, while the median time for placebo-treated patients was not estimable since less than half of the patients met this criterion by the end of the trial. For duloxetine-treated patients, median times to sustained 10%, 20%, and 30% improvements on the Maier subscale of the HAMD(17) were the same as those for the HAMD(17) total score: 14, 21, and 35 days, respectively. However, in other analyses, changes in core emotional symptoms as measured by subscales of the HAMD(17) were somewhat faster than changes in overall symptomatology. The probabilities of achieving a sustained 30% improvement (Maier subscale) at Week 1 for duloxetine- and placebo-treated patients were 16.2% vs. 4.8%, respectively (p < 0.001). The corresponding probabilities of sustained improvement at Weeks 2 and 3 for duloxetine were 32.5% and 45.4%, respectively, compared to 12.8% and 21.4% for placebo ((p < 0.001 for both comparisons).The absence of an active comparator limits the conclusions which can be drawn regarding the rapidity of onset of clinically meaningful improvement. However, results from the present investigation may be useful to clinicians in consideration of treatment options for individual patients." @default.
• W2118309105 created "2016-06-24" @default.
• W2118309105 creator A5019090648 @default.
• W2118309105 creator A5042304299 @default.
• W2118309105 creator A5057661359 @default.
• W2118309105 creator A5064184690 @default.
• W2118309105 creator A5070367435 @default.
• W2118309105 date "2005-03-01" @default.
• W2118309105 modified "2023-10-10" @default.
• W2118309105 title "Onset of action for duloxetine 60 mg once daily: double-blind, placebo-controlled studies" @default.
• W2118309105 cites W1971393265 @default.
• W2118309105 cites W1977722472 @default.
• W2118309105 cites W1982377331 @default.
• W2118309105 cites W1982721912 @default.
• W2118309105 cites W1990161259 @default.
• W2118309105 cites W1994024655 @default.
• W2118309105 cites W1998088135 @default.
• W2118309105 cites W1999522182 @default.
• W2118309105 cites W2000076844 @default.
• W2118309105 cites W2005021105 @default.
• W2118309105 cites W2030680920 @default.
• W2118309105 cites W2048361493 @default.
• W2118309105 cites W2054124000 @default.
• W2118309105 cites W2058667310 @default.
• W2118309105 cites W2059502536 @default.
• W2118309105 cites W2061378977 @default.
• W2118309105 cites W2063291862 @default.
• W2118309105 cites W2063900798 @default.
• W2118309105 cites W2072447647 @default.
• W2118309105 cites W2080024239 @default.
• W2118309105 cites W2080230064 @default.
• W2118309105 cites W2082298277 @default.
• W2118309105 cites W2082645204 @default.
• W2118309105 cites W2091679283 @default.
• W2118309105 cites W2094034945 @default.
• W2118309105 cites W2114613490 @default.
• W2118309105 cites W2120140544 @default.
• W2118309105 cites W2148756669 @default.
• W2118309105 cites W2169741270 @default.
• W2118309105 cites W2319982487 @default.
• W2118309105 cites W2510592686 @default.
• W2118309105 cites W4254230094 @default.
• W2118309105 cites W4299844232 @default.
• W2118309105 doi "https://doi.org/10.1016/j.jpsychires.2004.05.005" @default.
• W2118309105 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/15589564" @default.
• W2118309105 hasPublicationYear "2005" @default.
• W2118309105 type Work @default.
• W2118309105 sameAs 2118309105 @default.
• W2118309105 citedByCount "48" @default.
• W2118309105 countsByYear W21183091052012 @default.
• W2118309105 countsByYear W21183091052013 @default.
• W2118309105 countsByYear W21183091052014 @default.
• W2118309105 countsByYear W21183091052015 @default.
• W2118309105 countsByYear W21183091052017 @default.
• W2118309105 countsByYear W21183091052018 @default.
• W2118309105 countsByYear W21183091052019 @default.
• W2118309105 countsByYear W21183091052022 @default.
• W2118309105 countsByYear W21183091052023 @default.
• W2118309105 crossrefType "journal-article" @default.
• W2118309105 hasAuthorship W2118309105A5019090648 @default.
• W2118309105 hasAuthorship W2118309105A5042304299 @default.
• W2118309105 hasAuthorship W2118309105A5057661359 @default.
• W2118309105 hasAuthorship W2118309105A5064184690 @default.
• W2118309105 hasAuthorship W2118309105A5070367435 @default.
• W2118309105 hasConcept C118552586 @default.
• W2118309105 hasConcept C126322002 @default.
• W2118309105 hasConcept C138496976 @default.
• W2118309105 hasConcept C142724271 @default.
• W2118309105 hasConcept C15744967 @default.
• W2118309105 hasConcept C204787440 @default.
• W2118309105 hasConcept C27081682 @default.
• W2118309105 hasConcept C2776000289 @default.
• W2118309105 hasConcept C2777198177 @default.
• W2118309105 hasConcept C2780764818 @default.
• W2118309105 hasConcept C2910564767 @default.
• W2118309105 hasConcept C42219234 @default.
• W2118309105 hasConcept C535046627 @default.
• W2118309105 hasConcept C558461103 @default.
• W2118309105 hasConcept C71924100 @default.
• W2118309105 hasConcept C83849319 @default.
• W2118309105 hasConceptScore W2118309105C118552586 @default.
• W2118309105 hasConceptScore W2118309105C126322002 @default.
• W2118309105 hasConceptScore W2118309105C138496976 @default.
• W2118309105 hasConceptScore W2118309105C142724271 @default.
• W2118309105 hasConceptScore W2118309105C15744967 @default.
• W2118309105 hasConceptScore W2118309105C204787440 @default.
• W2118309105 hasConceptScore W2118309105C27081682 @default.
• W2118309105 hasConceptScore W2118309105C2776000289 @default.
• W2118309105 hasConceptScore W2118309105C2777198177 @default.
• W2118309105 hasConceptScore W2118309105C2780764818 @default.
• W2118309105 hasConceptScore W2118309105C2910564767 @default.
• W2118309105 hasConceptScore W2118309105C42219234 @default.
• W2118309105 hasConceptScore W2118309105C535046627 @default.
• W2118309105 hasConceptScore W2118309105C558461103 @default.
• W2118309105 hasConceptScore W2118309105C71924100 @default.
• W2118309105 hasConceptScore W2118309105C83849319 @default.
• W2118309105 hasIssue "2" @default.
• W2118309105 hasLocation W21183091051 @default.

• next